MXPA02005173A - Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea. - Google Patents

Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea.

Info

Publication number
MXPA02005173A
MXPA02005173A MXPA02005173A MXPA02005173A MXPA02005173A MX PA02005173 A MXPA02005173 A MX PA02005173A MX PA02005173 A MXPA02005173 A MX PA02005173A MX PA02005173 A MXPA02005173 A MX PA02005173A MX PA02005173 A MXPA02005173 A MX PA02005173A
Authority
MX
Mexico
Prior art keywords
association
decrease
diseases
bone mass
remedies
Prior art date
Application number
MXPA02005173A
Other languages
English (en)
Inventor
Maruyama Takayuki
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MXPA02005173A publication Critical patent/MXPA02005173A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describe una composicion farmaceutica para el tratamiento de enfermedades asociadas con una disminucion en la masa osea que comprende un agonista EP4 como ingrediente activo. Un agonista EP4 que incluye un compuesto que tiene un esqueleto de prostaglandina como un representante, tiene una accion promotora sobre la formacion osea, por lo cual es util para el tratamiento y/o prevencion de enfermedades asociadas con una disminucion en la masa osea.
MXPA02005173A 1999-11-24 2000-11-22 Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea. MXPA02005173A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP33349099 1999-11-24
JP2000056534 2000-03-01
JP2000119188 2000-04-20
PCT/JP2000/008235 WO2001037877A1 (fr) 1999-11-24 2000-11-22 Medicaments pour des affections liees a la perte de masse osseuse

Publications (1)

Publication Number Publication Date
MXPA02005173A true MXPA02005173A (es) 2004-02-26

Family

ID=27340604

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02005173A MXPA02005173A (es) 1999-11-24 2000-11-22 Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea.

Country Status (16)

Country Link
US (1) US6891062B2 (es)
EP (1) EP1232757B1 (es)
JP (1) JP3705360B2 (es)
KR (1) KR100654653B1 (es)
CN (1) CN1262309C (es)
AT (1) ATE452640T1 (es)
AU (1) AU783939B2 (es)
CA (1) CA2391526A1 (es)
DE (1) DE60043587D1 (es)
ES (1) ES2337333T3 (es)
HU (1) HUP0203590A3 (es)
MX (1) MXPA02005173A (es)
NO (1) NO20022442L (es)
NZ (1) NZ519101A (es)
TW (1) TWI247606B (es)
WO (1) WO2001037877A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1408961T3 (da) * 2001-07-16 2007-11-05 Hoffmann La Roche 2 pyrrolidon-derivater som prostanoide agonister
IL159996A0 (en) 2001-07-23 2004-06-20 Ono Pharmaceutical Co Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
KR20050012221A (ko) * 2001-11-12 2005-01-31 오노 야꾸힝 고교 가부시키가이샤 프로스타글란딘 유도체를 유효성분으로 하는 국소 투여용지속성 필름형 제제
EP1878741A3 (en) * 2002-05-23 2008-02-20 Theratechnologies Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
AU2003233297A1 (en) * 2002-05-23 2003-12-12 Theratechnologies Inc Antagonistic peptides of prostaglandin e2 receptor subtype ep4
WO2006075690A1 (ja) * 2005-01-14 2006-07-20 Ono Pharmaceutical Co., Ltd. 安定な医薬組成物
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
US20090074844A1 (en) 2005-04-28 2009-03-19 Ono Pharmaceutical Co., Ltd. Trenadermal absorption preparation
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
RU2425876C2 (ru) 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
US9402852B2 (en) * 2006-10-20 2016-08-02 Children's Medical Center Corporation Method to enhance tissue regeneration
EP2085088A4 (en) * 2006-10-26 2012-08-29 Ono Pharmaceutical Co ADHESIVE PREPARATION
CN101686985A (zh) 2007-05-08 2010-03-31 国立大学法人浜松医科大学 含有ep4激动剂的细胞毒性t细胞的活化剂
US20110206781A1 (en) * 2008-05-28 2011-08-25 Zon Leonard I Method to modulate hematopoietic stem cell growth
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
EP2454227B1 (en) 2009-07-13 2020-08-19 Patheon API Services Inc. Synthesis of prostanoids
ES2682255T3 (es) 2011-12-02 2018-09-19 Fate Therapeutics, Inc. Métodos mejorados de tratamiento de isquemia
CN112375734A (zh) 2011-12-02 2021-02-19 菲特治疗公司 增强的干细胞组合物
WO2014015247A1 (en) 2012-07-19 2014-01-23 Cayman Chemical Company, Inc. Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
WO2014150602A1 (en) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
EP3235817B1 (en) 2013-03-15 2018-12-12 Cayman Chemical Company, Incorporated Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
AU2014290512A1 (en) 2013-07-19 2015-11-12 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
CA2925927C (en) 2013-09-30 2022-09-06 George Petros Yiannikouros Novel synthesis routes for prostaglandins and prostaglandin intermediates using metathesis
MX2018003462A (es) 2015-09-22 2018-09-06 Graybug Vision Inc Compuestos y composiciones para el tratamiento de trastornos oculares.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507961A (ja) * 1996-12-20 2000-06-27 ファイザー・インク Ｅｐ２受容体サブタイプ選択性のプロスタグランジンｅ２アゴニストによる骨格障害の予防と治療
JPH10265454A (ja) * 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
GB2330307A (en) * 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
US6043275A (en) * 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6586468B1 (en) 1998-09-14 2003-07-01 Ono Pharmaceutical Co., Ltd. ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient
EP1121133A1 (en) * 1998-10-15 2001-08-08 Merck & Co., Inc. Methods for stimulating bone formation

Also Published As

Publication number Publication date
EP1232757A1 (en) 2002-08-21
KR20020059774A (ko) 2002-07-13
US20040209848A1 (en) 2004-10-21
JP3705360B2 (ja) 2005-10-12
CN1262309C (zh) 2006-07-05
CA2391526A1 (en) 2001-05-31
NO20022442D0 (no) 2002-05-23
AU783939B2 (en) 2006-01-05
EP1232757B1 (en) 2009-12-23
EP1232757A4 (en) 2004-06-16
KR100654653B1 (ko) 2006-12-07
DE60043587D1 (de) 2010-02-04
NO20022442L (no) 2002-07-24
HUP0203590A2 (hu) 2003-03-28
TWI247606B (en) 2006-01-21
WO2001037877A1 (fr) 2001-05-31
NZ519101A (en) 2004-04-30
ATE452640T1 (de) 2010-01-15
AU1548501A (en) 2001-06-04
CN1424918A (zh) 2003-06-18
HUP0203590A3 (en) 2006-07-28
ES2337333T3 (es) 2010-04-23
US6891062B2 (en) 2005-05-10

Similar Documents

Publication Publication Date Title
MXPA02005173A (es) Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea.
AU3990797A (en) Sustained release formulation
AU2002318759A1 (en) Remedies for diseases with bone mass loss having EP4 agonists as the active ingredient
MY133996A (en) Compounds for the treatment of ischemia
MXPA04000757A (es) Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo.
HK1049671A1 (en) Substituted indoles.
PT915898E (pt) Forma i cristalina de claritromicina
AP9901478A0 (en) Compounds for the treatment of ischemia.
FI963232A0 (fi) Antimikrobisena aineena käytettävä hapotettu nitriitti
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
BR0100558A (pt) Composições e métodos para tratar a osteoporose
NZ516513A (en) Nitric oxide donors for inducing neurogenesis
SE9802208D0 (sv) Novel compounds
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
EP0861663A3 (en) Osteoclastgenic inhibitory agent comprising interleukin-18
BR0013416A (pt) Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado
WO2001041747A3 (de) Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
SE9802209D0 (sv) Novel compounds
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
SE0000303D0 (sv) Novel compounds
GB9505082D0 (en) Medicament
MXPA02003731A (es) Derivados novedosos de acido fusidico.
WO2003024486A1 (fr) Traitements de la perte osseuse

Legal Events

Date Code Title Description
FG Grant or registration